| DC47618 |
PRMT5-IN-10
|
PRMT5-IN-10 has promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex. |
| DC47617 |
EED ligand 1
|
EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase. |
| DC47615 |
PRMT5-IN-9
|
PRMT5-IN-9 is a novel PRMT5 inhibitor for treating cancer, with an IC50 of 0.01 μM. |
| DC47613 |
PRMT5-IN-12
|
PRMT5-IN-12 shows remarkable inhibitory activity on PRMT5. |
| DC47612 |
PRMT5-IN-11
|
PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex in the (sub)micromolar range. |
| DC47611 |
PRMT5-IN-14
|
PRMT5-IN-14 is a PRMT5 inhibitor to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations. |
| DC47610 |
PRMT5-IN-3
|
PRMT5-IN-3 is a PRMT5 inhibitor that exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents. |
| DC47609 |
PRMT1-IN-1
|
PRMT1-IN-1 is a PRMT1 inhibitor. |
| DC47608 |
EZH2-IN-2
|
EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity. |
| DC47264 |
MS67
|
MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a Kd of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects. |
